Life Sciences Hiring Demand Is Recovering Faster Than Specialists Are Moving
- The U.S. labor market cooled in Q3: payrolls rose by only 29,000 in September, hiring slowed from its spring peak, and the national quit rate held at a low 1.9%.
- Life sciences employment held steady and grew modestly: scientific R&D services reached 918,300 jobs, and chemical manufacturing, which includes pharma, reached 905,500, rising in every month of the quarter.
- The 2025 restructuring wave is fading. BioSpace reported August biopharma layoffs down roughly 90% year over year, while M&A deals rose 63% in the first half.
- Demand is returning to a talent pool that is not moving. The gap is widest in regulatory affairs, medical affairs, pharmacovigilance, and quality, where Q4 searches will run longer and counteroffers will be more common.
Life Sciences Demand Is Returning to a Market Where Few Specialists Are Moving
Three signals from Q3 point the same way. Biopharma layoffs have fallen sharply, deal activity is up, and chemical manufacturing employment rose in every month of the quarter. At the same time, the national quit rate sits at 1.9%, so the experienced professionals pharma and biotech teams want to hire are mostly staying where they are.
For organizations with a filing, launch, or scale-up on the calendar, that combination makes Q4 a harder hiring quarter than the headline numbers suggest. The data below shows where demand is coming back, and where the talent to meet it is hardest to reach.
The Broader Labor Market Cooled Through Q3
In the spring, the March JOLTS report showed U.S. hiring surging to 5.6 million, the highest level since February 2024. By late summer, that momentum had faded. Employers made about 5.19 million hires in August, a hire rate of 3.3%, while job openings held near 7.08 million, according to the Bureau of Labor Statistics.
The September jobs report confirmed the slowdown. Total nonfarm payrolls grew by just 29,000, unemployment edged up to 4.2%, and July and August were revised down by a combined 60,000 jobs. Across the quarter, the economy added roughly 152,000 jobs.
The number that matters most for life sciences hiring is the quit rate. Quits held at 1.9% in August, low by historical standards. JOLTS does not break out pharma and biotech on their own, but the national rate sets the tone: fewer professionals are voluntarily changing employers, which means smaller active candidate pools, more counteroffers, and longer searches for experienced specialists.
U.S. job openings, hires, quits, and layoffs, August 2026
Layoffs Are Easing, Deals Are Rising
The 2025 restructuring cycle hit life sciences harder than most industries, with BioSpace counting more than 43,000 biopharma employees affected by layoffs. The 2026 picture looks different.
According to BioSpace, the first half of 2026 saw 58% fewer companies announce workforce reductions than the first half of 2025, even though the total number of affected employees was similar because of a few large restructurings. By August, layoffs had fallen roughly 90% year over year, and BioSpace’s Q2 analysis found job postings continuing to rise.
The cuts have not disappeared. Novo Nordisk disclosed in September that its workforce reduction would reach about 13,000, and several smaller biotechs cut deeply after clinical or partnership setbacks. The pattern, however, has shifted toward targeted decisions around specific programs. Deal activity supports that read: BioSpace reported 52 M&A deals in the first half of 2026, up from 32 a year earlier.
Biopharma layoffs and deal activity, 2026 vs. 2025
Life Sciences Employment Is Growing Slowly, With Demand Concentrated in a Few Places
Scientific research and development services employment stood at 918,300 in September, up 2,000 for the month and about 6,100 (0.7%) from a year earlier.
Scientific research and development services employment, September 2025 to September 2026
Chemical manufacturing, the BLS industry that includes pharmaceutical and medicine manufacturing, employed 905,500 people in September, up from 900,300 a year earlier and higher in each month of Q3.
Chemical manufacturing employment, including pharmaceutical and medicine manufacturing, September 2025 to September 2026
Modest headline growth hides where demand is concentrated. BioSpace reports that science and R&D, clinical, and engineering roles are leading postings, with Massachusetts and California showing the strongest demand. Employers are also competing for a newer profile: professionals who can bridge biology, machine learning, data, and engineering. Those candidates are scarce, and most are already employed.
Four Roles Sit Where Returning Demand Meets the Smallest Talent Pools
The roles under the most pressure heading into Q4 are the ones where rising demand meets the fewest available candidates.
Regulatory affairs. NDA and BLA submission timelines are fixed, and the pool of professionals with hands-on submission experience remains small. Rising M&A adds to that demand, since integration typically creates its own wave of regulatory hiring. When several sponsors approach filings at the same time, they compete for the same people.
Medical science liaisons and medical affairs leaders. Specialty and rare disease MSL roles are among the slowest to fill in life sciences, and a 1.9% quit rate makes experienced MSLs even harder to move. Most strong candidates are established in their territories and will weigh a counteroffer seriously.
Pharmacovigilance specialists. This shortage predates the current cycle, and international sourcing adds credential verification and compliance complexity. With churn this low, few experienced PV professionals are entering the market on their own.
Quality and manufacturing operations. Chemical manufacturing employment rose every month of Q3 as new domestic capacity comes online, while GMP compliance, process validation, and scale-up experience for biologics and cell and gene therapy remain constrained. Quality hires often set the pace for how quickly new capacity can produce, which is why life sciences manufacturing recruiting works best when it starts alongside the facility plan.
What the Q3 Data Means for Q4 Hiring Plans
A 1.9% quit rate changes the math on every specialist search. Most qualified candidates are employed and not looking, so searches depend on direct outreach rather than job postings, and offers need to anticipate counteroffers. Searches started on a typical timeline in this market tend to finish late.
Rising deal activity creates two talent problems at once. Acquiring companies need to keep key people at the acquired organization through integration, and they need to fill the regulatory, quality, and commercial roles that integration exposes. Both draw from the same constrained pools.
Demand is concentrating where competition is already highest. Lab-based and manufacturing roles require on-site presence, and field roles depend on territory coverage. The deepest talent pools in Boston and Cambridge, the San Francisco Bay Area, San Diego, and the New Jersey and Philadelphia corridor also carry the most competition, so organizations hiring there should benchmark compensation against local competitors rather than national ranges.
Signals to Watch Heading Into Q4
Three data points will show whether the market is loosening. The September JOLTS report on November 3 will show whether the quit rate moves off 1.9%, the first sign that specialists are becoming more willing to change employers. The October jobs report on November 6 will update payroll trends along with the R&D and chemical manufacturing employment series. BioSpace’s ongoing layoff and M&A tracking will show whether first-half deal momentum carried into the second half.
Internally, the measures that reflect this market most directly are offer acceptance rate, candidates lost to counteroffers, and time to first slate on specialist roles. When few people are moving, those numbers surface problems weeks before time to fill does.
Precision Will Matter More Than Volume in Q4
Layoffs are down, deal activity is up, and the specialists late-stage programs need are staying where they are. In that environment, the advantage goes to organizations that know where candidates are, what will move them, and how quickly the process has to run to meet a fixed date.
Want a clearer read on how these conditions affect the specific roles and markets on your hiring plan? Connect with the PrincetonOne Life Sciences team to start the conversation.
Get Started
